Biohaven Pharmaceutical Holding Company Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biohaven Pharmaceutical Holding Company Ltd.
A drastic risk-off pullback in the public market can close an IPO window while private biotechs aspiring for either a public debut or an acquisition by big pharma may be stymied by their stale valuations.
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
News that the Australian biotech's paxalisib did not meet pre-defined criteria to continue into the second stage of a major glioblastoma platform trial saw Kazia's stock crash, but investor reaction appears to be excessive.
- Controlled Release
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Biohaven Pharmaceuticals, Inc.
- Biohaven Therapeutics Ltd.
- Kleo Pharmaceuticals Inc.
- Portage Biotech Inc.
- Portage Glasgow Limited (PGL)